路透7月21日 - Agios Pharmaceuticals(AGIO.O)周二表示,由于中期临床试验结果未能确立支持继续研发的差异化特征,该公司将停止其镰状细胞病治疗药物的研发。
路透7月21日 - Agios Pharmaceuticals(AGIO.O)周二表示,由于中期临床试验结果未能确立支持继续研发的差异化特征,该公司将停止其镰状细胞病治疗药物的研发。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.